Hans Eriksson

affiliated with the university, MD, PhD, MBA

Research

Research areas and keywords

Clinical neuroscience, mood disorders, anxiety disorders, bipolar disorder, schizophrenia

Selected research outputs

Post hoc analysis of a randomised, placebo-controlled, active-reference 6-week study of brexpiprazole in acute schizophrenia. Marder SR, Eriksson H, Zhao Y, Hobart M. In : Acta Neuropsychiatr. 2020 Feb 14:1-6.

Remote assessment of disease and relapse in major depressive disorder (RADAR-MDD): a multi-centre prospective cohort study protocol. Matcham F, Barattieri di San Pietro C, Bulgari V, de Girolamo G, Dobson R, Eriksson H, Folarin AA, Haro JM, Kerz M, Lamers F, Li Q, Manyakov NV, Mohr DC, Myin-Germeys I, Narayan V, Bwjh P, Ranjan Y, Rashid Z, Rintala A, Siddi S, Simblett SK, Wykes T, Hotopf M; RADAR-CNS consortium. In : BMC Psychiatry. 2019 Feb 18;19(1):72.

Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants.  Thase ME, Youakim JM, Skuban A, Hobart M, Augustine C, Zhang P, McQuade RD, Carson WH, Nyilas M, Sanchez R, Eriksson H. In: J Clin Psychiatry. 2015 Sep;76(9):1224-31.  

Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study.  Thase ME, Youakim JM, Skuban A, Hobart M, Zhang P, McQuade RD, Nyilas M, Carson WH, Sanchez R, Eriksson H. In : J Clin Psychiatry. 2015 Sep;76(9):1232-40  

Efficacy and Safety of Brexpiprazole for the Treatment of Acute Schizophrenia: A 6-Week Randomized, Double-Blind, Placebo-Controlled Trial.  Correll CU, Skuban A, Ouyang J, Hobart M, Pfister S, McQuade RD, Nyilas M, Carson WH, Sanchez R, Eriksson H. In : Am J Psychiatry. 2015 Sep 1;172(9):870-80.  

A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia.  Kane JM, Skuban A, Ouyang J, Hobart M, Pfister S, McQuade RD, Nyilas M, Carson WH, Sanchez R, Eriksson H. In : Schizophr Res. 2015 May;164(1-3):127-35.  

Two Phase III randomised double-blind studies of fixed-dose TC-5214 (dexmecamylamine) adjunct to ongoing antidepressant therapy in patients with major depressive disorder and an inadequate response to prior antidepressant therapy.  Möller HJ, Demyttenaere K, Olausson B, Szamosi J, Wilson E, Hosford D, Dunbar G, Tummala R, Eriksson H. In : World J Biol Psychiatry. 2015 Oct;16(7):483-501.  

Lithium as add-on to quetiapine XR in adult patients with acute mania: a 6-week, multicenter, double-blind, randomized, placebo-controlled study.  Bourin MS, Severus E, Schronen JP, Gass P, Szamosi J, Eriksson H, Chandrashekar H. In : Int J Bipolar Disord. 2014 Nov 8;2:14.  

A randomized, double-blind study of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalized anxiety disorder.  Khan A, Joyce M, Atkinson S, Eggens I, Baldytcheva I, Eriksson H. In : J Clin Psychopharmacol. 2011 Aug;31(4):418-28.  

Extended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment for generalized anxiety disorder: a long-term, randomized, placebo-controlled trial.  Katzman MA, Brawman-Mintzer O, Reyes EB, Olausson B, Liu S, Eriksson H. In : Int Clin Psychopharmacol. 2011 Jan;26(1):11-24.  

Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: a placebo-controlled, randomized study.  Bortnick B, El-Khalili N, Banov M, Adson D, Datto C, Raines S, Earley W, Eriksson H. In : J Affect Disord. 2011 Jan;128(1-2):83-94.  

Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial.  Liebowitz M, Lam RW, Lepola U, Datto C, Sweitzer D, Eriksson H. In : Depress Anxiety. 2010 Oct;27(10):964-76.